@article{5af40a85c09e4903b5b509aaff0498a7,
title = "Resilience-based Integrated IBD Care Is Associated With Reductions in Health Care Use and Opioids",
abstract = "Background & Aims: Integrated inflammatory bowel disease (IBD) care is effective but not routinely implemented. Validated methods that simultaneously address mind and body targets such as resilience may improve access and outcomes. We describe the development and implementation of the GRITT method and its impact on resilience, health care utilization (HCU), and opioid use in IBD. Methods: Consecutive patients from an academic IBD center were evaluated for low resilience on the basis of provider referral. Low resilience patients were invited to participate in the GRITT program. Primary outcome was % reduction in HCU. Secondary outcomes were change in resilience and corticosteroid and opioid use. Patients were allocated into 2 groups for analysis: GRITT participants (GP) and non-participants (NP). Clinical data and HCU in the year before enrollment were collected at baseline and 12 months. One-way repeated measures multivariate analysis of covariance evaluated group × time interactions for the primary outcome. Effect size was calculated for changes in resilience over time. Results: Of 456 screened IBD patients 394 were eligible, 184 GP and 210 NP. GP had greater reduction in HCU than NP: 71% reduction in emergency department visits, 94% reduction in unplanned hospitalizations. There was 49% reduction in opioid use and 73% reduction in corticosteroid use in GP. Resilience increased by 27.3 points (59%), yielding a large effect size (d = 2.4). Conclusions: Mind-body care that focuses on building resilience in the context of IBD care may be a novel approach to reduce unplanned HCU and opioid use, but large, multicenter, randomized controlled trials are needed.",
keywords = "Crohn's Disease, Depression, Emergency Department Use, Hospitalizations, Mind-Body Intervention, Opioid Use, Positive Psychology, Ulcerative Colitis",
author = "Laurie Keefer and Ksenia Gorbenko and Tina Siganporia and Laura Manning and Stacy Tse and Anthony Biello and Ryan Ungaro and Cohen, {Louis J.} and Cohen, {Benjamin L.} and Dubinsky, {Marla C.}",
note = "Funding Information: Conflicts of interest These authors disclose the following: LK: Consultant to AbbVie, Lilly, Takeda and Trellus Health; advisory board member for Reckitt Health; research funding from PCORI and NIH; co-founder and equity ownership Trellus Health, Inc. RCU: Advisory board member or consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda; research support from AbbVie, Boehringer Ingelheim, and Pfizer. BLC: Advisory boards and consultant for AbbVie, Celgene-Bristol Myers Squibb, Pfizer, Sublimity Therapeutics, Takeda, TARGET RWE; speaker: AbbVie. MCD: Consultant and advisory Board Member: AbbVie, Arena, BMS, Celgene, Gilead, Janssen, Pfizer, Prometheus Labs, Takeda, Target RWE; co-founder, board of director, and equity ownership Trellus Health Inc. The remaining authors disclose no conflicts. Funding Information: Funding Mount Sinai Innovation Partners (MSIP) supported the development of the digital resilience scoring tool through its I3 Accelerator Fund. RCU is funded by an NIH Career Development Award (K23KD111995-01A1). Funding Information: Conflicts of interest These authors disclose the following: LK: Consultant to AbbVie, Lilly, Takeda and Trellus Health; advisory board member for Reckitt Health; research funding from PCORI and NIH; co-founder and equity ownership Trellus Health, Inc. RCU: Advisory board member or consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda; research support from AbbVie, Boehringer Ingelheim, and Pfizer. BLC: Advisory boards and consultant for AbbVie, Celgene-Bristol Myers Squibb, Pfizer, Sublimity Therapeutics, Takeda, TARGET RWE; speaker: AbbVie. MCD: Consultant and advisory Board Member: AbbVie, Arena, BMS, Celgene, Gilead, Janssen, Pfizer, Prometheus Labs, Takeda, Target RWE; co-founder, board of director, and equity ownership Trellus Health Inc. The remaining authors disclose no conflicts. Funding Mount Sinai Innovation Partners (MSIP) supported the development of the digital resilience scoring tool through its I3 Accelerator Fund. RCU is funded by an NIH Career Development Award (K23KD111995-01A1). Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = aug,
doi = "10.1016/j.cgh.2021.11.013",
language = "English",
volume = "20",
pages = "1831--1838",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "8",
}